UNS - Unilife Corporation

[pacestick]

Sorry I didnt supply references

March 10, 2010
Unilife and Stason Pharmaceuticals Sign Asian Distribution Agreement for the Unitract(TM) 1mL Safety Syringe
Initial order for 1 million units of the Unitract(TM) 1mL Syringe

LEWISBERRY, Pa., March 10, 2010 /PRNewswire via COMTEX News Network/ -- Unilife Corporation ("Unilife" or "Company") (Nasdaq: UNIS; ASX: UNS) today announced that it has signed an exclusive five-year agreement with Stason Pharmaceuticals Inc ("Stason"), a U.S.-based pharmaceutical company, to market the Unitract(TM) 1mL safety syringe ("Product") in Japan, China and Taiwan ("designated territories"). Stason's Taiwan-based strategic alliance affiliate, Standard Chem. and Pharm. Co., LTD ("Standard"), will act as the primary distributor of the product within these designated territories.

This agreement includes a requirement for Stason to purchase a minimum of one million units of the Unitract(TM) 1mL syringe per year during the term of the contract (subject to annual review). Stason is placing an immediate annual order with Unilife for the purchase of one million units of the Unitract(TM) 1mL syringe. Other countries within South-East Asia may be added to the list of designated territories where Stason has exclusive rights to sell the Product if the parties reach agreement on minimum orders for those countries.

Stason CEO Harry Fan stated: "We believe strongly in the market for the Unitract(TM) safety syringe and its potential to help decrease needlestick injuries around the world. We are excited to be one of the first distributors of this revolutionary device and to have the opportunity to exclusively distribute the Unitract(TM) syringe to our customers in Asia. In particular, we believe there are significant opportunities for pharmaceutical companies to gain a competitive market advantage by supplying their injectable drugs in kits containing the drug vial and units of the Unitract(TM) 1mL Syringe."

Stason Vice President, Corporate Development Diana Wood, added: "This strategic alliance with Unilife also represents our joint vision where drugs and devices come together to deliver medications more comfortably to patients and more safely for hospital staff."

Unilife CEO Alan Shortall stated: "With manufacturing of our Unitract(TM) 1mL syringes underway at our FDA-certified facility in Pennsylvania, we are excited to move forward with this initial distribution agreement and initial order for one million Unitract(TM) safety syringes with Stason Pharmaceuticals and Standard Chem. and Pharma. We believe there is a significant market opportunity for our safety syringes throughout the Asia-Pacific region, especially within fast-growing nations where there is both an appreciation for innovative US-manufactured technology and a desire to use premium safety medical devices which can minimize the transmission of blood-borne pathogens such as HIV and hepatitis C within healthcare facilities.

"We look forward to working closely with Stason and Standard to develop these markets and secure sustained rates of growth for the sale of our products across Asia. We are also continuing to negotiate with other pharmaceutical and healthcare companies across the world for distribution rights for the Unitract(TM) 1mL syringes. We expect that additional agreements will be signed in conjunction with the continued global rollout of the Unitract(TM) 1mL syringes," Mr. Shortall said.

The Unitract(TM) range of 1mL syringes is the world's first and only known syringe that allows operators to control the speed of automatic needle retraction directly from the patient's body into the barrel of the syringe where it is locked in place. The products are well positioned to help prevent the transmission of blood-borne diseases such as HIV and hepatitis C via aerosol dispersal, needlestick injuries and syringe reuse. Primary target markets of the products include healthcare facilities, pharmaceutical companies and patients who self-administer prescription medication.

Also, while Unilife continues to have a relationship with Shanghai Kindly Enterprise Development Group Company Ltd ("KDL") for the assembly of its Unitract(TM) 1mL syringes within China on a per order basis, other agreements between Unilife and KDL relating to the distribution of the product within China and other agreed territories have expired. Stason has advised the Company of a preference to receive units of the Unitract(TM) 1mL syringe that are assembled at Unilife's FDA-registered facilities in the U.S. State of Pennsylvania.

AND more recently

Unilife Commences U.S. Sales of Unitract ® 1mL Syringes
IMCO, Inc., with its U.S. Member Healthcare Distributors, to be Initial Launch Partner
LEWISBERRY, Pa., Nov. 15, 2010 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (Nasdaq: UNIS; ASX: UNS) today announced that it has commenced U.S. sales of its Unitract ® range of 1mL safety syringes.
Unilife and Independent Medical Co-Op, Inc. ("IMCO"), one of the largest medical supply co-operatives in the U.S., have entered into a preferred, non-exclusive marketing program for the sale of Unitract 1mL syringes to U.S. healthcare facilities.
IMCO's member distributors provide medical equipment and supplies to healthcare facilities across the U.S. and Canada. Many of IMCO's Members focus primarily on the physician and long-term care markets. These two segments of the U.S. healthcare market consume a significant proportion of all 1mL safety syringes manufactured each year.
Unilife considers IMCO to be an ideal partner to support the initial launch of its Unitract range of 1mL syringes in the U.S. It is now processing for shipment a number of initial purchase orders it has received from IMCO member distributors. Discussions with a number of additional IMCO members are currently under way as part of an integrated nationwide launch for the Company's FDA-certified range of products.
Mr. Alan Shortall, CEO of Unilife, stated, "Unilife is delighted to announce the commencement of U.S. sales and shipments for its Unitract range of 1mL syringes. It is appropriate that U.S. sales have commenced in the same month that healthcare industry leaders are celebrating the 10-year anniversary of the signing of the Federal Needlestick Safety and Prevention Act. Despite these laws mandating the use of safety syringes within U.S. healthcare facilities, many healthcare workers continue to remain at risk of needlestick injury, including injuries from existing safety syringe technologies. We believe the automatic and operator controlled safety features that are fully integrated within the barrel of our Unitract range of 1mL syringes make them ideally positioned to help address the unmet needs of healthcare workers.
"IMCO is ideally positioned to act as a preferred partner to support our initial launch activities, given their focus and market reach within those healthcare sectors where the use of 1mL safety syringes is greatest. We look forward to working with IMCO and their members to successfully introduce our Unitract 1mL syringes to healthcare facilities across the U.S."
Mr. Bill McLaughlin, CEO of IMCO stated, "Unilife's line of retractable syringes is outstanding in every way and will clearly become an important factor in the market, improving the quality of patient care and the personal safety of clinicians everywhere".

 

[Sean K]

Sorry I didnt supply references

Don't mean to be pedantic RSM but aren't they distribution and marketing agreements, not actual sales to customers. The one million pre-order is so they can be sold, if they find buyers isn't it? Forgive me I'm not sure how these things work.

 

[pacman]

With UNS at an all time low, its looking fine for a long position. Things will pick up in about 12 months if we can hold that long.

 

[UMike]

With UNS at an all time low, its looking fine for a long position. Things will pick up in about 12 months if we can hold that long.

Can I ask how it is looking fine and why "things" will pick up in about 12 months.

Glad i got out while it was still UNI.

 

[pacman]

Mike, you own a footy team? Nice signature ;-)

UNS are being bought up by BlackRock, they have moved into their new factory and have yet to sign up the other 16 pharmaceuticals, with a product as good they have why not?

 

[UMike]

Not that I am a chartist but the 6mt (and 1 year for that mater) is not looking that great.

Still on my watch list but I am fully invested (and those third party payments are killing me)



Good luck with it

 

[pacman]

Yeah, the market is nervous, ASX has been dangerous place this past year. Lucky I have US stock.

 

[Noddy]

Have watched this share for most of last year, and the share price just keeps tracking lower and lower.
Can't see any signs of a turnaround at this stage.
Company seems to have a good product, but the market doesn't like it.
And that's all that matters really.

 

[pacman]

Noddy

how right you are, all those people injecting insulin three time a day, you would think this would be enough to drive it upwards....

 

[pacestick]

nilife Appoints Dr. Ramin Mojdeh as Chief Operating Officer

Former BD Pharmaceutical Systems Leader to Help Drive Unilife Towards Global Leadership Position

YORK, Pa., Feb. 3, 2011 /PRNewswire/ -- Unilife Corporation ("Unilife" or the "Company") (Nasdaq: UNIS; ASX: UNS) today announced that it has appointed Dr. Ramin Mojdeh, formerly Vice President and General Manager of Becton Dickinson (BD) Pharmaceutical Systems, North America, and Worldwide Vice President of Research and Development, BD Medical, as its new Chief Operating Officer and Executive Vice President, effective February 7, 2011.

Dr. Mojdeh comes to Unilife with more than 25 years of business leadership experience across multiple industries, including 18 years in the design, development, manufacturing, sales and marketing of therapeutic and diagnostic medical devices for several multinational companies, including BD, GE Healthcare and Boston Scientific (formerly "Guidant Corporation"). He has developed and maintained strong relationships with many pharmaceutical manufacturers that utilize prefilled syringes for their injectable drugs and vaccines.

As COO, Dr. Mojdeh will lead Unilife's operating team as the Company prepares to enter its next phase of business expansion with the commercial production of the Unifill ® ready-to-fill (prefilled) syringe this quarter, and its supply to pharmaceutical customers. Dr. Mojdeh will also help to expand and accelerate discussions with pharmaceutical companies regarding the Unifill syringe, as well as the commercialization of a number of key pipeline products being developed by the Company.

Dr. Mojdeh spent the last eight years working with BD, one of the world's leading suppliers of medical devices, including prefilled syringes. He served as the Vice President and General Manager of BD Medical, Pharmaceutical Systems, North America from 2008 to 2010. In this role, he directed all aspects of the North America operations including sales, marketing, business development, commercial development, finance, R&D, manufacturing, operations, quality assurance, regulatory affairs, legal affairs and human resources.

During this time, Dr. Mojdeh served as a key board member of the Business Strategy Council that led the worldwide business growth strategy for BD Pharmaceutical Systems, whose annual revenues exceeded $1 billion. He also led the creation of an innovative new growth business for BD Pharmaceutical Systems in advanced drug delivery.

From 2002 to 2008, Dr. Mojdeh held the position of the Worldwide Vice President of Research and Development for BD Medical, responsible for technology and product innovation and commercialization for the business areas of medical surgical systems, diabetes care, pharmaceutical systems and ophthalmic systems with combined annual revenues of over $4 billion. During this time, he led the process of revamping the product development functions for BD Medical.

He was also a board member of BD Ventures Inc., the venture capital arm of BD, which oversaw all technology and innovation activities across BD. Furthermore, he has served as the Chairman of the Advanced Drug Delivery Council, aimed at identifying and developing new growth strategies in the drug delivery device space.

Prior to his work with BD, Dr. Mojdeh held the position of Business Director, Invasive Cardiology at GE Healthcare in 2002, and spent ten years with Guidant Corporation, where he held several management positions including Business Director, Advanced Patient Management from 1999 to 2002 and Business Director, Advanced Patient Monitoring System from 1996 to 1999.

Mr. Alan Shortall, Chief Executive Officer of Unilife, stated, "The addition of Dr. Mojdeh to our executive team and as the leader of our operational divisions is a clear indication of Unilife's commitment to rapid growth and the production of the highest quality medical devices. Our ability to attract executives with the experience and reputation of Dr. Mojdeh is an affirmation of the potential for Unilife's innovative product line. Dr. Mojdeh has extensive experience in driving product innovation, manufacturing advanced medical devices and launching new business ventures. His detailed knowledge of how prefilled syringes are manufactured and supplied to the highest industry standards should help us secure, expand and consolidate strong commercial relationships with many of the world's largest pharmaceutical and healthcare companies.

"The appointment of Dr. Mojdeh as COO comes at the right time for Unilife. We are now preparing to commence commercial production of the Unifill syringe, with several key sections of the manufacturing system now either in place or being prepared for delivery to our new facility in York. And the commissioning of our cleanrooms and the requalification of our Unitract ® 1mL syringe assembly line are now approaching completion. In addition, Dr. Mojdeh's extensive experience working with pharmaceutical companies will be invaluable as our commercial discussions are now accelerating with a significant number of pharmaceutical companies relating to the Unifill syringe, as well as some of our pipeline products. The appointment of Dr. Mojdeh puts us in a strong position to take Unilife to the next level and attain a true global leadership position in the pharmaceutical market for drug delivery devices."

Dr. Ramin Mojdeh commented, "I am extremely pleased to join the executive team of such a unique and innovative company as Unilife. Unilife is developing an exceptional portfolio of innovative products, with the Unifill syringe in particular representing game-changing technology within the pharmaceutical market for prefilled syringes. With Unilife's new global headquarters complete and commercial production of the Unifill syringe about to commence, the Company is in an extraordinary position to now undertake significant expansion on an international scale. I am excited to have an opportunity to help Unilife expand its commercial relationships and capitalize on its tremendous growth potential."

Dr. Mojdeh received his Ph.D. in Computer Science from the University of Minnesota, Minneapolis Minnesota, and his MBA from Kellogg Graduate School of Management, Northwestern University, Evanston, Illinois.

About Unilife Corporation

Unilife Corporation is a U.S.-based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for Unilife products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. These patent-protected syringes incorporate automatic, operator-controlled needle retraction features which are fully integrated within the barrel, and are designed to protect those at risk of needlestick injuries and unsafe injection practices. Unilife is ISO 13485-certified and has FDA-registered medical device manufacturing facilities in Pennsylvania.

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.

General: UNIS-G

 

[pacestick]

http://crystalra.com/pdf/UNIS_Update_02-07-2011.pdf

This is the latest analyst report from crystal; research interesting enough they show the sales to imco

http://www.unilife.com/index.php?option=co...&Itemid=290

This link is to the latest and final photos of the new facility note the internal photos are showing two production lines presumably the 1ml and the prefill

 

[Sean K]

http://crystalra.com/pdf/UNIS_Update_02-07-2011.pdf

This is the latest analyst report from crystal; research interesting enough they show the sales to imco

This has confirmed my view of the company.

Fine print at the end of the 'report'.

Legal Notes and Disclosures: This Quarterly Update has been prepared by Crystal Research Associates, LLC (“CRA”) with the assistance of Unilife Corp. (“Unilife” or “the Company”) based upon information provided by the Company. CRA has not independently verified such information. In addition, CRA has been compensated by Unilife Corp. in cash of twenty-five thousand U.S. dollars and eighteen thousand seven hundred fifty Warrants in 2009 to purchase Unilife stock for its services in creating the base report, for updates, and for printing costs.

It's a paid advertisement disguised as 'research' by an 'analyst'.

Be alarmed, not alert.

 

[Slipperz]

Well spotted kennas. Strange how the UNS story is unfolding.

Seems to have a great product and a good partner in SA.

Production facilities looking good.

And no orders???

 

[pacman]

anyone know how the shareholders meeting went yesterday?

 

[LeeTV]

York County company quickly expanding, making more jobs
Dara Rees
abc27 News
Posted: Mar 04, 2011 3:30 AM
Updated: Mar 04, 2011 9:19 AM


A York County company has doubled in size for the past two years. Its health care safety products are in demand, and that means even more jobs will be coming to the midstate!

The brand new Unilife building in Manchester Township is just beginning to grow. "Unilife Corporation has grown 100% each year for the last three years. So we've gone two years ago from employing about 40 people to employing close to 170 people," said CEO or Unilife Corporation Alan Shortall.

Their main product is safety syringes with retractable needles that Shortall says keeps doctors and nurses safe. "There are over 600,000 recorded needle stick injuries in health care industries in the USA every year," he said. "There are estimated to be over 35 health care workers [who] die every year from needle stick injuries."

By federal law, health care facilities must provide safety syringes. Unilife is ready. There are also patents pending for Unilife's pre-filled, retractable syringes, which Shortall says will cut hospital costs.

All this means booming business for the company, and more local people getting jobs. Neil Clifford says he's happy to join the staff and use his machinist skills on life-saving products, right in his own backyard. "It's wonderful to be close to home and have a short commute," said Clifford.

Jobs at Unilife are for every skill and education level, and hundreds are expected to be added over the next few years.

"I think the energy that we're hopefully helping to contribute to our community will allow people to get past the difficult time we've all suffered for the last two or three years and start to look at the horizon," said Shortall. "There are opportunities out there. And they are just as much in central Pennsylvania as they are anywhere else."

Production at Unilife is expected to really pick up in about three months. That's when a big round of hiring is expected to happen. But company representatives said they are always looking for skilled workers and hard working people.

 

[pacestick]

This has confirmed my view of the company.

Fine print at the end of the 'report'.

It's a paid advertisement disguised as 'research' by an 'analyst'.

Be alarmed, not alert.

another report this time from Griffin securities

http://www.proactivenewsroom.com/De...ocs/Griffin+UNIS+Update+Report+03+10+2011.pdf

 

[pacestick]

Up over 12 % last night on the Nasdaq should see a jump on ASX monday

http://stockpar.com/index.php?id=2

nasdaq now 12.42% ahead of australia

 

[LeeTV]

Unilife Commences Initial Production of Unifill Prefilled Syringe

Companies:Unilife Corporation.Related Quotes
Symbol Price Change
UNS.AX 0.85 0.00


Press Release Source: Unilife Corporation On Tuesday March 29, 2011, 9:55 am EDT
YORK, Pa., March 29, 2011 /PRNewswire/ -- Unilife Corporation ("Unilife" or the "Company") (Nasdaq:UNIS - News) today announced it has commenced initial production of the Unifill ® ready-to-fill (prefilled) syringe at its FDA-registered manufacturing facility in York, Pennsylvania.

The initial production of the Unifill syringe, the world's first prefilled syringe with safety features fully integrated within the glass barrel, will enable Unilife to further accelerate discussions with more than 20 pharmaceutical companies. These pharmaceutical companies are at various stages of review in the potential use of the Unifill syringe with a number of approved and pipeline injectable drugs and vaccines across more than a dozen therapeutic classes.

Once Unilife completes final product validation activities for the Unifill syringe during the second quarter of 2011, the Company can begin to fulfill initial sales orders to its existing pharmaceutical partner. The supply and sale of the Unifill syringe to other interested pharmaceutical companies is expected to commence shortly afterwards.

Initial production batches are expected to be utilized by pharmaceutical companies and contract manufacturing organizations (which fill prefilled syringes with injectable drugs on behalf of their pharmaceutical clients) for a number of activities. This will include the initiation of drug stability studies, market evaluations, and validating the integration of the product into fill-finish systems currently used to load a measured dose of an injectable drug or vaccine into equivalent standard prefilled syringes.

Mr. Alan Shortall, CEO of Unilife, said, "We look forward to being in a position to begin fulfilling initial sales orders for the Unifill syringe towards the end of June, and consolidating relationships with a number of interested pharmaceutical companies during the rest of the year. We are proud to be commencing initial production of the Unifill syringe nine months ahead of our original schedule, having successfully met every quarterly milestone since the industrialization program began in July 2008.

"We are now entering an exciting new chapter in Unilife's emergence as a global leader for innovative drug delivery devices. Unilife has built the operational capabilities to serve as a full-service partner to pharmaceutical companies in the delivery of innovative device solutions that can generate powerful brand differentiation, protect healthcare workers and enhance patient care.

"We believe our capacity for developing market-driven and customized devices, our agility in satisfying customer requirements, and our reliability in delivering on project milestones can serve as a unique competitive advantage to which pharmaceutical partners will gravitate. The commercial supply of the Unifill syringe, and the commercialization of other products within our expanding pipeline should be just the start of us forging a strong industry reputation as a preferred pharmaceutical partner for device innovation," concluded Mr. Shortall.

The Unifill ® Syringe

The Unifill syringe is the world's first prefilled syringe with safety features fully integrated within the glass barrel. It is designed for integration into fill-finish systems used by pharmaceutical manufacturers to load a measure dose of an injectable drug or vaccine into equivalent standard prefilled syringes, and features USP compliant materials inside the fluid path. An automatic (passive) needle retraction mechanism is activated in the Unifill syringe upon full dose delivery, allowing operators to control the speed of needle retraction directly from the body into the barrel to virtually eliminate the risk of infection from potential transmission modes such as needlestick injuries or splatter. The Unifill syringe is designed for compact handling and convenient disposal by either healthcare workers or patients that self-administer prescription medication. As a unique primary drug container offering optimal protection to healthcare workers and their patients, the Unifill syringe is strongly positioned to help pharmaceutical companies generate powerful brand differentiation within competitive therapeutic drug classes, and optimize product lifecycles.

Pharmaceutical Market for Prefilled Syringes

Prefilled syringes serve as a primary drug container for approximately 50 injectable drugs and vaccines currently marketed by more than 20 pharmaceutical companies. More than 2.4 billion prefilled syringes are used every year according to Greystone Associates, with the market growing at approximately 12% per year. Unilife considers the pharmaceutical market for prefilled syringes to be the fastest-growing, least congested and most profitable sector of the global syringe industry. To comply with legislation across international markets, such as the U.S. and Europe which mandate the use products that can protect healthcare workers from needlestick injuries, pharmaceutical companies currently attach ancillary safety products onto standard prefilled syringes. These ancillary safety products can increase pharmaceutical packaging, transport and disposal volumes by up to 70%

 

[Sean K]

Once Unilife completes final product validation activities for the Unifill syringe during the second quarter of 2011, the Company can begin to fulfill initial sales orders to its existing pharmaceutical partner.

Hang on.

Didn't they have sales of XX$$ all sewn up?

Now it depends on 'validation'?

So, there is some fine print in the contract that has not been presented by the looks.

 

[pacestick]

Hang on.

Didn't they have sales of XX$$ all sewn up?

Now it depends on 'validation'?

So, there is some fine print in the contract that has not been presented by the looks.

The validation of an assembly line is standard practice It was listed in the contract of purchase at the time . Mikron do not get their final payment untill they can prove that contract meets the specifications in the contract . It would be irresponsible of all parties involved to A. pay for the line without validating it and B sign sales contracts without having the performance of the line validated first.It covers a number of things including most important of all for sales contract the speed of operation . The question is not whether there will be a sales contract with sanofi aventis but quantities and delivery dates . It was included in announcements at the time the contract was made.